← Back to Search

Monoclonal Antibodies

MT1013 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Shaanxi Micot Technology Limited Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Capable of consent.
Male or female, non-smoker (no use of tobacco or nicotine products within 3 months prior to screening), ≥18 and ≤55 years of age, with BMI >18.0 and <30.0 kg/m2 and body weight ≥45.0 kg for males and females.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up three months
Awards & highlights

Study Summary

This study is evaluating whether a new drug may be safe for human use.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~three months
This trial's timeline: 3 weeks for screening, Varies for treatment, and three months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To evaluate the safety and tolerability of MT1013 for injection in healthy adult subjects.
Secondary outcome measures
PD
PK
To characterize the pharmacodynamics (PD) of MT1013 for injection in healthy adult subjects
+1 more

Trial Design

5Treatment groups
Experimental Treatment
Group I: 5th cohortExperimental Treatment1 Intervention
MT1013 injection at 20 mg.
Group II: 4th cohortExperimental Treatment1 Intervention
MT1013 injection at 15 mg.
Group III: 3rd cohortExperimental Treatment1 Intervention
MT1013 injection at 10 mg.
Group IV: 2nd cohortExperimental Treatment1 Intervention
MT1013 injection at 5 mg.
Group V: 1st cohortExperimental Treatment1 Intervention
MT1013 injection at 2.5 mg.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MT1013
2021
Completed Phase 1
~40

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Shaanxi Micot Technology Limited CompanyLead Sponsor
4 Previous Clinical Trials
98 Total Patients Enrolled
WCCT GlobalIndustry Sponsor
13 Previous Clinical Trials
863 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~11 spots leftby Mar 2025